Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.

Nat Rev Immunol · 2018 · PMC5918154 · PMID 29379211

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Notably, a neutralizing anti-RSV sdAb (ALX-0171) that targets an epitope overlapping that bound by palivizumab recently showed a trend towards a therapeutic effect in a phase I and IIa clinical trial based on reduced viral loads and clinical symptoms in hospitalized RSV-infected infants.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.